Publications by authors named "Sei Shu"

Claim this Profile
P
Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Preclinical Models.
Natsumi Kawasaki, Sei Shu, Mayu Tomita, Xiaoxiao Liu, Shigeki Yoshiura

EJHaem· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
Yoriko Yamashita-Kashima, Sei Shu, Masahiro Osada, Takaaki Fujimura, Shigeki Yoshiura

Cancer Chemother Pharmacol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
Yoriko Yamashita-Kashima, Sei Shu, Masahiro Osada, Takaaki Fujimura, Shigeki Yoshiura

Cancer Chemother Pharmacol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models.
Sei Shu, Yoriko Yamashita-Kashima, Mieko Yanagisawa, Hayao Nakanishi, Yasuhiro Kodera

Anticancer Drugs· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The balance of forces generated by kinesins controls spindle polarity and chromosomal heterogeneity in tetraploid cells.
Sei Shu, Makoto Iimori, Takeshi Wakasa, Koji Ando, Hiroshi Saeki

J Cell Sci· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Yoriko Yamashita-Kashima, Yasushi Yoshimura, Takaaki Fujimura, Sei Shu, Mieko Yanagisawa

Cancer Chemother Pharmacol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Koh Furugaki, Marie Mochizuki, Mirei Kohno, Sei Shu, Naoki Harada

BMC Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer.
Sei Shu, Makoto Iimori, Ryota Nakanishi, Tomoko Jogo, Hiroshi Saeki

In Vivo· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model.
Yoriko Yamashita-Kashima, Sei Shu, Keigo Yorozu, Yoichiro Moriya, Naoki Harada

Oncol Lett· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.
Toru Kawamoto, Kazunori Ishige, Melanie Thomas, Yoriko Yamashita-Kashima, Sei Shu, Shunichi Ariizumi

J Gastroenterol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization.
Yoriko Yamashita-Kashima, Sei Shu, Keigo Yorozu, Kaoru Hashizume, Yoichiro Moriya

Gastric Cancer· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yoriko Yamashita-Kashima, Sei Shu, Naoki Harada, Kaori Fujimoto-Ouchi

Oncol Rep· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis